IL143295A0 - New cancer treatments - Google Patents

New cancer treatments

Info

Publication number
IL143295A0
IL143295A0 IL14329599A IL14329599A IL143295A0 IL 143295 A0 IL143295 A0 IL 143295A0 IL 14329599 A IL14329599 A IL 14329599A IL 14329599 A IL14329599 A IL 14329599A IL 143295 A0 IL143295 A0 IL 143295A0
Authority
IL
Israel
Prior art keywords
cell lines
prostate cancer
heterogeneity
cancer treatments
new cancer
Prior art date
Application number
IL14329599A
Other languages
English (en)
Original Assignee
Onyvax Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onyvax Ltd filed Critical Onyvax Ltd
Publication of IL143295A0 publication Critical patent/IL143295A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
IL14329599A 1998-12-10 1999-12-09 New cancer treatments IL143295A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9827103.4A GB9827103D0 (en) 1998-12-10 1998-12-10 New cancer treatments
PCT/GB1999/004135 WO2000033870A2 (en) 1998-12-10 1999-12-09 New cancer treatments

Publications (1)

Publication Number Publication Date
IL143295A0 true IL143295A0 (en) 2002-04-21

Family

ID=10843925

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14329599A IL143295A0 (en) 1998-12-10 1999-12-09 New cancer treatments
IL143295A IL143295A (en) 1998-12-10 2001-05-22 Immunological substances and preparations containing them for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL143295A IL143295A (en) 1998-12-10 2001-05-22 Immunological substances and preparations containing them for the treatment of cancer

Country Status (19)

Country Link
US (1) US6699483B1 (no)
EP (1) EP1137434B1 (no)
JP (1) JP4607330B2 (no)
KR (1) KR100612552B1 (no)
AT (1) ATE412425T1 (no)
AU (1) AU777969B2 (no)
CA (1) CA2354046C (no)
CZ (1) CZ20012033A3 (no)
DE (1) DE69939837D1 (no)
ES (1) ES2315024T3 (no)
GB (1) GB9827103D0 (no)
HU (1) HUP0104857A3 (no)
IL (2) IL143295A0 (no)
MX (1) MXPA01005815A (no)
NO (1) NO326035B1 (no)
NZ (1) NZ512005A (no)
PL (1) PL348829A1 (no)
WO (1) WO2000033870A2 (no)
ZA (1) ZA200104163B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075073A2 (en) * 2000-04-01 2001-10-11 Onyvax Limited Prostate cell lines and their use
EP1337149A4 (en) 2000-10-27 2005-10-12 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
ATE421328T1 (de) * 2002-02-22 2009-02-15 Intracel Recources Llc Sterile immunogene nicht-tumorigene tumorzell- zusammensetzungen und verfahren
US7176022B2 (en) * 2002-12-20 2007-02-13 Cell Genesys, Inc. Directly injectable formulations which provide enhanced cryoprotection of cell products
US20050019336A1 (en) 2003-07-23 2005-01-27 Dalgleish Angus George Human prostate cell lines in cancer treatment
MXPA06002159A (es) * 2003-08-26 2006-05-22 Becton Dickinson Co Metodos para la administracion intradermica de agentes terapeuticos.
NZ627167A (en) 2003-10-16 2015-10-30 Stephen John Ralph Immunomodulating compositions and uses therefor
US8257715B1 (en) 2004-08-26 2012-09-04 University Of Notre Dame Tissue vaccines and uses thereof
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
US8802113B2 (en) * 2005-10-27 2014-08-12 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US8778360B2 (en) * 2005-10-27 2014-07-15 University Of Notre Dame Extracellular matrix cancer vaccine adjuvant
US9308252B2 (en) * 2005-10-27 2016-04-12 Cook Biotech, Inc. Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
US8778362B2 (en) 2005-10-27 2014-07-15 University Of Notre Dame Anti-tumor/cancer heterologous acellular collagenous preparations and uses thereof
GB0601598D0 (en) * 2006-01-26 2006-03-08 Stathopoulos Apostolos Method
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
US20110250218A1 (en) * 2008-10-29 2011-10-13 Fong Lawrence H Disease-Associated Antigens and Methods of Use Thereof
WO2010132867A1 (en) 2009-05-15 2010-11-18 Irx Therapeutics, Inc. Vaccine immunotherapy
AU2010328197B2 (en) 2009-12-08 2015-07-16 Irx Therapeutics, Inc. Method of reversing immune suppression of Langerhans cells
US8846059B2 (en) 2009-12-08 2014-09-30 University Of Notre Dame Extracellular matrix adjuvant and methods for prevention and/or inhibition of ovarian tumors and ovarian cancer
US20110150934A1 (en) * 2009-12-18 2011-06-23 University Of Notre Dame Ovarian Tumor Tissue Cell Preparations/Vaccines for the Treatment/Inhibition of Ovarian Tumors and Ovarian Cancer
CN105850982B (zh) * 2016-04-29 2018-08-17 绍兴市人民医院 一种新型组织冻存液
CN105850981B (zh) * 2016-04-29 2018-07-20 绍兴市人民医院 冻存肿瘤组织的方法
EP4006145A4 (en) * 2019-07-24 2023-08-23 Slbigen Inc. PRODUCTION PROCESS OF AN IMPORTALIZED STEM CELL LINE AND ITS USE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
ES2191784T3 (es) * 1995-12-28 2003-09-16 Univ Johns Hopkins Med Vacunas de tumores de citocinas paracrinas alogenicas.
CA2245099C (en) * 1996-02-02 2007-01-09 Suzanne L. Topalian Immortal human prostate epithelial cell lines and clones and their applications in the research and therapy of prostate cancer
EP1125133A1 (en) * 1998-11-03 2001-08-22 Cell Genesys, Inc. Novel cancer-associated antigens and methods of their identification
GB9827104D0 (en) * 1998-12-10 1999-02-03 Onyvax Ltd New cancer treatments

Also Published As

Publication number Publication date
CA2354046A1 (en) 2000-06-15
KR20010090873A (ko) 2001-10-19
PL348829A1 (en) 2002-06-17
MXPA01005815A (es) 2003-04-02
HUP0104857A2 (hu) 2002-04-29
NO20012818D0 (no) 2001-06-07
WO2000033870A2 (en) 2000-06-15
DE69939837D1 (de) 2008-12-11
NO326035B1 (no) 2008-09-01
HUP0104857A3 (en) 2004-04-28
US6699483B1 (en) 2004-03-02
NZ512005A (en) 2004-01-30
CA2354046C (en) 2011-02-15
CZ20012033A3 (cs) 2001-10-17
AU777969B2 (en) 2004-11-04
GB9827103D0 (en) 1999-02-03
ES2315024T3 (es) 2009-03-16
JP4607330B2 (ja) 2011-01-05
ATE412425T1 (de) 2008-11-15
KR100612552B1 (ko) 2006-08-11
IL143295A (en) 2006-04-10
ZA200104163B (en) 2002-02-04
NO20012818L (no) 2001-06-07
JP2002531521A (ja) 2002-09-24
AU1668700A (en) 2000-06-26
WO2000033870A3 (en) 2000-08-17
EP1137434B1 (en) 2008-10-29
EP1137434A2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
GB9827103D0 (en) New cancer treatments
MXPA03001634A (es) Polipeptido tumoral cripto.
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
DE69534946D1 (de) Verwendung von nackten Polynukleotiden zur Herstellung eines Medikaments für die Behandlung von Tumoren
BG101284A (en) Compounds and methods for cancer treatment
MXPA03001389A (es) Composiciones y metodos para la terapia y diagnostico de malignidades asociadas con her-2/neu.
IL231810A (en) History of itensinoid and pharmaceutical preparations containing the same methods of preparation and use thereof for cancer treatment
EP1578380A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
HK1109638A1 (en) Dr5 antibodies and uses thereof dr5
HK1102544A1 (en) Use of herbal compositions in the manufacture of medicine for treating prostate cancer
WO2004112825A3 (en) Combinations of tumor-associated antigens for the treatment of various types of cancers
WO2007112316A3 (en) Mycobacterial immunotherapy for cancer treatment
WO2018064588A3 (en) Tert immunogenic compositions and methods of treatment using the same
MX2021005400A (es) Terapia del cancer con celulas inmunitarias anti-ptk7.
WO2011056566A3 (en) Compounds and methods for treatment of cancer
Nikolsky Break in the cosmic ray spectrum or confinement violation near 10 6 TeV?
HUP0104568A2 (hu) Humán prosztata sejtvonalak a daganatok kezelésében
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
WO2000033871A3 (en) Use of human prostate tumour cell lines in cancer treatment
MXPA02011563A (es) Composicionesy metodos para la terapia y diagnostico de cancer de seno.
Yang et al. Effect of chronic endogenous antigen stimulation on CAR T cell persistence and memory formation
EP0951475A4 (en) Vaccine against metastatic colorectal cancer.
EP4252852A3 (en) Methods and materials for treating cancer
WO2004015063A3 (en) Amplification and overexpression of oncogenes
WO2001056612A3 (en) Animal model for testing of immunotherapies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed